Home
About Us
Core Team
Development History
Corporate Culture
S&T
Research Areas
Technology Platforms
Research and Development
Marketed Products
R&D Products
R&D Pipeline
Academic Progress
Blog
Company News
Media Reports
Join Us
Post-Doctoral Center
Contact Us
Big News | Warmly congratulate the approval of Nivolumab (Tecentriq®) for pancreatic cancer indication
View details
→
[Case Study] Issue 249: Nilotinib Treatment for Tonsillar Cancer (Neoadjuvant)
Nimotuzumab Granted Second Indication for Treating Pancreatic Cancer
[Case Study] Issue 248: Nilotinib for Nasopharyngeal Carcinoma (Neoadjuvant Therapy)
[Happy Life Case] Issue 247: Nilotinib Treatment for Laryngeal Cancer
[Shengxin Case Report] Issue 246: Clinical Efficacy of Nilotinib Monotherapy in Palliative Treatment of Laryngeal Cancer – A Case Study